Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics' stock (FULC) has experienced significant positive movement in the past six months. The stock price increased by 161.19% over the last six months and 189.03% over the last 12 months, with a year-to-date return of 96.17%. As of October 21, 2025, the share price was $9.70. Positive clinical trial results from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) showed robust increases in fetal hemoglobin (HbF) and improvements in markers of hemolysis and anemia. Fulcrum Therapeutics is anticipated to post its Q3 2025 results before the market opens on Wednesday, October 29th, 2025, with analysts expecting earnings of ($0.29) per share. Several research firms have issued reports on FULC, with HC Wainwright reiterating a "buy" rating, Royal Bank of Canada lifting its price objective, and Leerink Partners setting a $20.00 price objective. The consensus rating for Fulcrum Therapeutics is "Moderate Buy" with an average price target of $11.20. As of June 30, 2025, the company reported $214.1 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2028.

The provided information does not indicate any specific demand seasonality for Fulcrum Therapeutics, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its "products" (drug candidates) are in development and not yet commercially available. The company's revenue and operational activities are driven by research and development milestones, clinical trial progress, and potential collaboration agreements, rather than seasonal fluctuations in product sales.

Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company focused on developing novel medicines by modulating gene control mechanisms for genetically defined rare diseases. Their product engine identifies drug targets to modulate gene expression. Pociredir, an oral small-molecule inhibitor of EED, is in clinical trials for sickle cell disease (SCD) and beta-thalassemia and has received FDA Fast Track and Orphan Drug designations for SCD. Losmapimod is being developed for facioscapulohumeral muscular dystrophy (FSHD).

Fulcrum Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States. Its primary operational footprint, including its corporate office and research and development activities, is based in Cambridge, MA, while focusing on therapies for global patient populations.

Information specifically detailing Fulcrum Therapeutics, Inc.'s "brand reputation" in the past year is not explicitly available in the provided search results. Positive developments, such as the promising results from the Phase 1b PIONEER trial for pociredir in sickle cell disease, would generally enhance its scientific and corporate reputation. The company's focus on "improving the lives of patients with genetically defined rare diseases" suggests a mission-driven approach that could contribute positively to its public image.

Fulcrum Therapeutics (NASDAQ: FULC) is primarily owned by institutional shareholders (100.57%) and Fulcrum Therapeutics insiders (61.21%), with a negligible percentage held by retail investors (0.00%). Ra Capital Management, L.P. is the largest individual shareholder, owning 31.85% of the company. Other major institutional and individual owners include TCG Crossover Management, LLC, Suvretta Capital Management, LLC, Adage Capital Partners GP, L.L.C., BlackRock, Inc., Nantahala Capital Management, LLC, Vanguard Group Inc, Dimensional Fund Advisors Lp, Mark J. Levin, and Third Rock Ventures III LP.